ProfileGDS4814 / ILMN_1906004
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 9% 4% 4% 4% 4% 21% 5% 7% 11% 8% 10% 23% 2% 27% 16% 20% 29% 11% 38% 10% 4% 7% 12% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)40.81659
GSM780708Untreated after 4 days (C2_1)38.74424
GSM780709Untreated after 4 days (C3_1)39.04554
GSM780719Untreated after 4 days (C1_2)38.95534
GSM780720Untreated after 4 days (C2_2)38.76434
GSM780721Untreated after 4 days (C3_2)43.682821
GSM780710Trastuzumab treated after 4 days (T1_1)39.48165
GSM780711Trastuzumab treated after 4 days (T2_1)40.10077
GSM780712Trastuzumab treated after 4 days (T3_1)41.316411
GSM780722Trastuzumab treated after 4 days (T1_2)40.4238
GSM780723Trastuzumab treated after 4 days (T2_2)41.133910
GSM780724Trastuzumab treated after 4 days (T3_2)44.253823
GSM780713Pertuzumab treated after 4 days (P1_1)37.91432
GSM780714Pertuzumab treated after 4 days (P2_1)44.906127
GSM780715Pertuzumab treated after 4 days (P3_1)42.664616
GSM780725Pertuzumab treated after 4 days (P1_2)43.597820
GSM780726Pertuzumab treated after 4 days (P2_2)45.428529
GSM780727Pertuzumab treated after 4 days (P3_2)41.377111
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)47.393838
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)41.220410
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)38.72694
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)40.06577
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)41.622812